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Abstract
 
Human immunodeficiency virus (HIV) type 1 Vpu is an integral membrane protein with a
unique affinity for 
 
 
 
TrCP (TrCP), a key member of the SkpI-Cullin-F-box E3 ubiquitin ligase
complex that is involved in the regulated degradation of cellular proteins, including I
 
 
 
B. Re-
markably, Vpu is resistant to TrCP-mediated degradation and competitively inhibits TrCP-
dependent degradation of I
 
 
 
B, resulting in the suppression of nuclear factor (NF)-
 
 
 
B activity
in Vpu-expressing cells. We now report that Vpu, through its interaction with TrCP, potently
contributes to the induction of apoptosis in HIV-infected T cells. Vpu-induced apoptosis is
specific and independent of other viral proteins. Mutation of a TrCP-binding motif in Vpu
abolishes its apoptogenic property, demonstrating a close correlation between this property of
Vpu and its ability to inhibit NF-
 
 
 
B activity. The involvement of NF-
 
 
 
B in Vpu-induced
apoptosis is further supported by the finding that the levels of antiapoptotic factors Bcl-xL, A1/
Bfl-1, and TNF receptor-associated factor (TRAF)1, all of which are expressed in an NF-
 
 
 
B–
dependent manner, are reduced and, at the same time, levels of active caspase-3 are elevated.
Thus, Vpu induces apoptosis through activation of the caspase pathway by way of inhibiting
the NF-
 
 
 
B–dependent expression of antiapoptotic genes.
Key words: TrCP • caspase • TNF-
 
 
 
 • Bcl-xL • TRAF1
 
Introduction
 
HIV-1 infection is generally associated with a progressive
decrease in the number of CD4
 
 
 
 T lymphocytes. This
phenomenon is presumably one of the key factors contrib-
uting to the virus-induced impairment of the host immune
response and is generally considered to be caused by pro-
grammed cell death (apoptosis; reference 1). In vitro, two
distinct mechanisms for the induction of apoptosis in
CD4
 
 
 
 T cells have been observed: one is the induction of
apoptosis in uninfected bystander cells; the second mecha-
nism involves the direct killing of infected cells by HIV-1
(1). Apoptosis of uninfected bystander cells can be caused
by gp120, which may induce aberrant T cell signaling
through binding to CD4 molecules on uninfected cells. In
addition, the secretion of HIV-encoded factors such as Tat,
Nef, or Vpr or the release from HIV-infected cells of cellu-
lar apoptosis-inducing factors such as Fas ligand, TNF-
 
 
 
,
or TNF-related apoptosis-inducing ligand were all found
to trigger apoptosis in uninfected bystander cells (1). One
of the viral factors known to induce direct killing of in-
fected cells in vitro is Vpr, which was found to induce cell
cycle arrest in the G2/M phase, followed by induction of
apoptosis (2–4). However, CD4
 
 
 
 T cells infected with 
 
vpr
 
-
defective HIV-1 still undergo apoptosis, suggesting that vi-
ral product(s) other than Vpr contribute to the induction of
apoptosis in infected cells (2, 3).
Vpu is a viral membrane protein that regulates the release
of virions from infected cells and induces degradation of
CD4 (5–7). These two functions of Vpu are mechanisti-
cally distinct (8, 9). In HIV-2, virus release is regulated by
the viral Env product thus compensating for the lack of a
 
vpu
 
 gene (10–12). In contrast, the ability of Vpu to induce
CD4 degradation has no functional complement in HIV-2
or simian IV viruses and thus constitutes one of the distin-
guishing characteristics of HIV-1. CD4 degradation re-
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Dr., MSC 0460 Bethesda, MD 20892-0460. Phone: 301-496-3132; Fax:
301-402-0226; E-mail: kstrebel@nih.gov 
1300
 
Vpu Induces Apoptosis in Infected Cells
 
quires the formation of ternary complexes between Vpu,
CD4, and 
 
 
 
TrCP (13, 14). 
 
 
 
TrCP (TrCP) is a component
of E3 ubiquitin ligase complexes (14) and regulates degra-
dation of various cellular substrates including 
 
 
 
-catenin or
I
 
 
 
B-
 
 
 
, the latter being a potent inhibitor of nuclear factor
(NF)
 
*
 
-
 
 
 
B (15). Unlike normal cellular substrates of TrCP,
which are directly targeted for degradation, Vpu is insensi-
tive to degradation and can form stable complexes with
TrCP (14). As a result, we found that Vpu is able to com-
petitively inhibit the cellular function of TrCP, including
the virus- or cytokine-induced degradation of I
 
 
 
B-
 
 
 
 (16).
Vpu did not inhibit the cytokine-mediated activation of
the I
 
 
 
B kinase, but instead interfered with the subsequent
TrCP-dependent degradation of phosphorylated I
 
 
 
B-
 
 
 
and resulted in a pronounced reduction of NF-
 
 
 
B activity
(16). NF-
 
 
 
B has a central role in the regulation of genes
involved in cell proliferation, cytokine production, as well
as in the regulation of apoptosis (17, 18). Therefore, Vpu
expression in HIV-1–infected cells could have a profound
impact on NF-
 
 
 
B regulated gene expression and thus
could contribute to the virus-induced cytopathic effects.
Based on these observations, we have explored in this
study the possible involvement of Vpu in HIV-1–induced
apoptosis. We found that in HIV-1–infected CD4
 
 
 
 T cells
Vpu contributed significantly to the induction of apoptosis.
Using an inducible expression system we found that the ef-
fect of Vpu on apoptosis was direct and did not require the
coexpression of other viral proteins. Analysis of cellular fac-
tors involved in the induction of apoptosis demonstrated
that Vpu downmodulated the NF-
 
 
 
B–dependent expres-
sion of antiapoptotic genes such as Bcl-xL and A1/Bfl-1.
Concomitantly, Vpu expression resulted in increased levels
of active caspase-3. These effects of Vpu involved an inter-
action with TrCP as evidenced by the fact that mutation of
the TrCP binding motif in Vpu abolished its apoptogenic
potential. These results suggest that Vpu promotes apopto-
sis through its inhibition of NF-
 
 
 
B.
 
Materials and Methods
 
Plasmids.
 
The full-length HIV-1 molecular clone pNL4–3
was used for the production of wild-type infectious virus. Con-
struction of the Env- and Vpu-defective variants pNL43-K1 (10)
and pNL4–3/Udel (6), respectively, was described previously.
Plasmid pNL4–3/U
 
2/6
 
 encodes a TrCP-binding deficient variant
of Vpu and carries two serine to alanine mutations in its cytoplas-
mic domain (S
 
52,56
 
A). Construction of this plasmid has been de-
scribed previously (8). To inactivate the 
 
env
 
 and/or 
 
vpr
 
 genes in
pNL4–3, pNL4–3/Udel, or pNL4–3/U
 
2/6
 
, frame-shift mutations
were introduced at a 
 
Kpn
 
I site (NL4–3 pos. 6343) in the 
 
env
 
 gene
or an 
 
EcoR
 
I site (NL4–3 pos. 5743) in the 
 
vpr
 
 gene (or both),
resulting in pNL43-K1/Udel (Env
 
 
 
, Vpu
 
 
 
), pNL43-K1/U
 
2/6
 
(Env-, Vpu-TrCP binding mutant), pNL43-EcK1/Udel (Vpr
 
 
 
,
Vpu
 
 
 
, Env
 
 
 
), or pNL43-EcK1/U
 
2/6
 
 (Vpr-, Env-, Vpu-TrCP
binding mutant). The plasmid pHCMV-G contains the vesicular
stomatitis virus glycoprotein G (VSV-G) gene under the tran-
scriptional regulation of the human cytomegalovirus immediate
early promoter and was used for the production of VSV-G
pseudotyped viruses.
 
Cells.
 
293T cells were maintained in DMEM containing
10% FBS. Jurkat cells were cultured in RPMI 1640 medium
supplemented with 10% FBS. HeLa cell lines for the inducible
expression of the CD4-Vpu chimeric proteins CD4U or
CD4U
 
2/6
 
 under the control of a tetracycline/doxycycline (Dox)
repressed promoter have been described previously (16). These
cells were maintained in complete DMEM medium supple-
mented with G418 (1 mg/ml), Dox (20 ng/ml), and hygromy-
cin (200 
 
 
 
g/ml). PBLs were isolated from leukapheresed blood
of HIV-seronegative donors by countercurrent centrifugal elu-
triation as described previously (19). CD4
 
 
 
 T lymphocytes were
purified using a magnetic bead system (Miltenyi Biotec) accord-
ing to the manufacturer’s instructions. The purity of the prepara-
tion was 
 
 
 
90% as determined by flow cytometry. The CD4
 
 
 
cells were then stimulated with phytohemagglutinin-P (Bacto) at
1 
 
 
 
g/ml in RPMI 1640 medium supplemented with 10% FBS
and 10 U/ml recombinant human IL-2 (Boehringer Mannheim)
for 2 d before infection.
 
Preparation of VSV-G Pseudotyped Viruses.
 
VSV-G pseudo-
typed viruses were produced in 293 T cells by cotransfection of
20 
 
 
 
g of pNL4–3 DNA, or one of its variants together with 2 
 
 
 
g
of pHCMV-G per 2 
 
 
 
 10
 
7
 
 cells in 75 cm
 
2
 
 tissue culture flasks.
Virus supernatants were harvested 48 h after transfection. Filtered
(0.45 
 
 
 
m Sterivex-HV filter; Millipore) supernatants were ultra-
centrifuged for 1 h at 25,000 rpm using an SW41 rotor (Beckman
Coulter). Concentrated viruses were suspended in RPMI 1640
medium. Virus stocks were quantified by reverse transcriptase as-
say and infectious titers were determined by MAGI assay (20).
 
Detection of HIV-1-infected Cells.
 
HIV-1–infected Jurkat cells
were fixed in 1% formaldehyde (in PBS) for 15 min at 4
 
 
 
C and
then permeabilized using FACS
 
®
 
 permeabilizing solution (Bec-
ton Dickinson) for 15 min at 4
 
 
 
C. The cells were incubated for
15 min at 4
 
 
 
C with 10 
 
 
 
g/ml of mouse IgG to block nonspecific
binding sites. Samples were then labeled with a PE-conjugated
anti–HIV-1 p24 mAb (KC57; Beckman Coulter) for 30 min at
4
 
 
 
C. Cells were then suspended in 1% formaldehyde and ana-
lyzed for fluorescence intensity by flow cytometry.
 
Analysis of Apoptosis and Cell Cycle.
 
Apoptotic cells were
identified by either annexin V binding (21, 22) or by staining with
the vital dye 7-amino-actinomycin D (7-AAD). Binding of an-
nexin V is observed in early and late apoptotic cells while staining
with 7-AAD is indicative of late apoptosis. To stain HeLa cells,
2 
 
 
 
 10
 
5
 
 cells were detached by treatment with Trypsin/EDTA
(0.05% Trypsin, 0.53 mM EDTA; Life Technologies) and sus-
pended in 300 
 
 
 
l of ice-cold annexin V binding buffer containing
Hepes-NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl
 
2
 
 (BD
PharMingen). Cells were then reacted for 15 min on ice with 5 
 
 
 
l
each of PE-conjugated annexin V (BD PharMingen) and 7-AAD
(BD PharMingen), followed immediately by flow cytometric
analysis. For analysis of HIV-1–infected Jurkat cells, the cells were
treated and analyzed as described for HeLa cells, except that cells
were fixed in 1% formaldehyde (in annexin V binding buffer) be-
fore FACS
 
®
 
 analysis to inactivate virus.
To detect fragmentation of chromosomal DNA, terminal
deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL)
 
*
 
Abbreviations used in this paper:
 
 7-AAD, 7-amino-actinomycin D;
 
 
 
c-
IAP, cellular inhibitor of apoptosis; Dox, doxycycline; MIP, macro-
phage inflammatory protein; m.o.i., multiplicity of infection; NF, nu-
clear factor; PI, propidium iodide; TRAF, TNFR-associated factor;
TUNEL, transferase dUTP nick end-labeling; RANTES, regulated on
activation, normal T cell expressed and secreted; VSV-G, vesicular sto-
matitis virus glycoprotein G. 
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assay was performed using an APO-DIRECT kit (BD PharMin-
gen). Reactions were done as per the manufacturer’s instructions.
For microscopic analysis of apoptosis-related phenotypic
changes of the nuclei, cells were stained with propidium iodide
(PI) as follows: HeLa cells grown on coverslips were fixed with
1% formaldehyde (in PBS) for 30 min at 4
 
 
 
C followed by incuba-
tion with 70% ethanol for 30 min at 4
 
 
 
C. Cells were then treated
with RNase A (1 mg/ml in PBS) for 15 min at 37
 
 
 
C before PI
was added to a final concentration of 50 
 
 
 
g/ml. PI staining con-
tinued for 15 min at room temperature before samples were
mounted on microscope slides for confocal microscopy.
For cell cycle analysis Jurkat cells were fixed in 1% formalde-
hyde (in PBS) and permeabilized using FACS
 
®
 
 permeabilizing so-
lution. The cells were washed and treated with RNaseA (1 mg/
ml in PBS) for 15 min at 37
 
 
 
C, followed by staining with PI (50
 
 
 
g/ml) for more 15 min at room temperature. Cells were then
analyzed by flow cytometry and the data were evaluated for cell
cycle status using the ModFit LT software (Becton Dickinson).
 
Detection of Active Caspase-3.
 
The active form of caspase-3
was detected using an active form-specific antibody. Briefly, HeLa
cells were detached by treatment with Trypsin/EDTA (0.05%
Trypsin, 0.53 mM EDTA; Life Technologies) and fixed in 1%
formaldehyde (in PBS) for 15 min at 4
 
 
 
C. Cells were permeabi-
lized using FACS
 
®
 
 permeabilizing solution for 15 min at 4
 
 
 
C.
The cells were then incubated for 15 min at 4
 
 
 
C with mouse IgG
(10 
 
 
 
g/ml) to block nonspecific binding followed by a 30-min
incubation at 4
 
 
 
C with a FITC-conjugated rabbit antiactive
caspase-3 polyclonal antibody (BD PharMingen). Finally, the
stained cells were fixed in 1% formaldehyde (in PBS) and analyzed
for fluorescence intensity using a FACSort™ (Becton Dickinson).
 
Western Blot Analysis.
 
Western blot analyses were performed
using the ECL detection system (Amersham Pharmacia Biotech)
as described previously (16). The Abs used were as follows: anti–
TNFR-associated factor (TRAF1) mAb (H-3; Santa Cruz Bio-
technology, Inc.); anticaspase-8 polyclonal antibody (BD Phar-
Mingen); anti–Bcl-xL mAb (2H12; BD PharMingen); anti-A1/
Bfl-1 polyclonal antibody (Santa Cruz Biotechnology, Inc.); anti–
 
 
 
-tubulin mAb (DM 1A; Sigma-Aldrich); anti-Vpu polyclonal
antibody (U2–3; reference 23); and anti-p24 capsid mAb (pro-
vided by S. Zolla-Pazner, AIDS Research and Reference Re-
agent Program, Division of AIDS, NIAID, NIH; reference 24).
 
Results
 
Vpu Promotes Apoptosis in HIV-1-infected Jurkat Cells.
 
In
the first set of experiments, Jurkat cells were single-cycle
infected with VSV-G-pseudotyped HIV-1NL4–3 (NL4–
3/G) at a multiplicity of infection (m.o.i.) of 5. Cells were
analyzed 48 h after infection for the induction of apoptosis
using annexin V and 7-AAD staining as markers (Fig. 1 A).
In mock-infected cultures, only 1.7% of the cells were an-
nexin V-positive with half of those cells also scoring posi-
tive for 7-AAD (Fig. 1 A, panel a). In contrast, in cultures
infected with NL4–3/G, 51.1% of the cells were in the
early phase of apoptosis (annexin V
 
 
 
 7-AAD
 
 
 
) and 28.8%
of the cells were already in the late phase of apoptosis (an-
nexin V
 
 
 
 7-AAD
 
 
 
; Fig. 1 A, panel b). To assess the rela-
tive impact of Env expression on the induction of apopto-
sis, Jurkat cells were infected with a VSV-G-pseudotyped
Env-defective variant, HIV-1NL43-K1 (Fig. 1 A, panel c).
The results showed that the proportion of cells found in
the early (48.1%) or late phase of apoptosis (24.4%) was
comparable to that in NL4–3/G-infected cells (compare
panels b and c). This indicates that the expression of HIV-1
Env is not a major factor in the induction of apoptosis in
our experimental system. Surprisingly, infection of Jurkat
cells by the pseudotyped Vpu-defective variant, NL4–3/
Udel/G (Fig. 1 A, panel d) showed a significant reduction
of annexin V- and 7-AAD-positive cells. In fact, the total
number of annexin V-positive cells was reduced by 
 
 
 
40%
in the absence of Vpu relative to wild-type virus (compare
Fig. 1 panels b and d). These results suggest that Vpu may
play a significant role in the induction of apoptosis in
HIV-1-infected cells. To ascertain that the results from
Fig. 1 A were not biased by different infection efficiencies,
we determined the intracellular expression levels of Gag
proteins for the cultures shown in Fig. 1 A by staining
with a p24 capsid (CA) antibody followed by flow cytom-
etry (Fig. 1 B). The results demonstrate that all cultures
(except mock) were infected with similar efficiency and
Figure 1. Vpu induces apoptosis in HIV-1–
infected Jurkat cells. Uninfected Jurkat cells (a)
or Jurkat cells infected with an m.o.i. of 5
with VSV-G-pseudotyped virus stocks of
(b) wild-type (WT) NL4–3, (c) NL43-K1
(Env ), or (d) NL4–3/Udel (Vpu ) variants
were used for this analysis. (A) Cultures were
analyzed 48 h after infection for the presence
of apoptotic cells by staining with 7-AAD
and PE-conjugated annexin V, followed by
flow cytometric analysis. Numbers represent
the percentages of cells in the respective
quadrants. (B) The same cultures were eval-
uated 24 h after infection for HIV-1 infec-
tion by intracellular p24 staining using
PE-conjugated mouse mAb to HIV-1 p24
followed by flow cytometry. Numbers rep-
resent the percentages of p24-positive cells.
The dotted lines in panels a–d represent p24-
staining of mock-infected cells. The solid
lines in panels a–d represent p24-staining of
infected cells. The results shown are repre-
sentative of three independent experiments. 
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produced comparable levels of p24 CA antigen, as deter-
mined by fluorescence intensity.
 
Vpu-induced Apoptosis Is Independent of HIV-1 Env or Vpr
and Requires a TrCP Binding Motif.
 
We have previously
shown that Vpu can act as a competitive inhibitor of TrCP
and, as a consequence, suppress the activation of NF-
 
 
 
B
(16). This effect is dependent on a motif in the cytoplasmic
domain of Vpu that includes two phosphoserine residues
and constitutes a binding domain for TrCP (14). To exam-
ine whether the inhibition of TrCP could be functionally
related to the Vpu-induced apoptosis observed in Fig. 1,
we compared the apoptotic potential of wild-type Vpu and
a TrCP binding mutant, Vpu
 
2/6. At the same time, we
wanted to compare the relative effects of Vpu with those of
Vpr, a known inducer of apoptosis (2, 3). Also, since Vpu
can affect surface transport of Env in CD4-expressing cells
(25) and to rule out second cycles of infection, we em-
ployed Env-defective viruses for the following experiment.
Env-defective virus preparations, pseudotyped with
VSV-G, lacking Vpu and/or Vpr expression or expressing
Vpu2/6 were prepared as described for Fig. 1 and used for
single-cycle infection of Jurkat cells. Intracellular p24
staining followed by FACS® analysis, as performed in Fig.
1, confirmed that infection efficiency and protein expres-
sion levels were comparable for all samples (data not
shown). As shown in Fig. 2 A, uninfected cells exhibited
only low levels ( 2%) of spontaneous apoptosis (Fig. 2 A,
panel a). In contrast, infection of Jurkat cells by Vpu- and
Vpr-expressing virus (panel b) induced severe apoptosis as
evidenced by the fact that 72% of the cells were positive
for annexin V within 48 h after infection. Deletion of Vpu
(Vpr , Vpu , panel c) or mutation of the TrCP binding
motif (Vpr , Vpu2/6, panel d) reduced the proportion of
annexin V-positive cells in the cultures to 39 and 45%, re-
spectively. Similarly, deletion of Vpr (Vpr , Vpu , panel
e) resulted in a marked reduction of annexin V  cells
(41%) relative to cultures expressing both Vpr and Vpu
(compare panels a and e). However, cultures infected with
viruses lacking both Vpr and Vpu (Vpr , Vpu , panel f) or
expressing Vpu2/6 (Vpr , Vpu2/6, panel g) exhibited even
lower levels of apoptotic cells (15 and 20%, respectively).
The residual apoptogenic property of HIV-1 lacking Env,
Vpu, and Vpr (panels f and g) presumably is due to the ex-
pression of other viral proteins such as Tat (1). Results of
Fig. 2 A indicate that Vpu and Vpr have the ability to in-
duce apoptosis with similar efficiency. Moreover, the data
show that Vpu-mediated apoptosis is not dependent on the
presence of Vpr, raising the question as to whether Vpu
mimics the activity of Vpr or induces apoptosis through a
novel mechanism. The results of this experiment are sum-
marized in Table I.
While the precise mechanism of Vpr-induced apoptosis
is currently unclear, it appears to be correlated with the
protein’s ability to induce cell cycle arrest in the G2 phase
Figure 2. Vpu-induced apop-
tosis is independent of HIV-1
Env or Vpr and requires a TrCP-
binding motif. Jurkat cells were
(a) mock-infected or infected
with an m.o.i. of 5 with VSV-G-
pseudotyped virus stocks of (b)
NL43-K1 (Env ), (c) NL43-K1/
Udel (Env , Vpu ), (d) NL43-
K1/U2/6 (Env , Vpu2/6), (e)
NL43-EcK1 (Env , Vpr ), (f)
NL43-EcK1/Udel (Env , Vpr ,
Vpu ), or (g) NL43-EcK1/U2/6
(Env , Vpr , Vpu2/6). (A) Cul-
tures were analyzed 48 h after
infection for apoptotic cells as in
Fig. 1 A. (B) The same cultures
were examined 24 h after infec-
tion for their cell cycle status by
propidium iodide staining fol-
lowed by flow cytometry. Simi-
lar results were obtained from
three independent experiments.1303 Akari et al.
(2, 3). Numerous steps in cell cycle control are regulated by
proteasome-dependent degradation of cell cycle regulators
(26). Because of the transdominant negative effect of Vpu
on the function of TrCP, a known regulator of protea-
some-dependent protein degradation (14), it is possible that
Vpu competitively suppresses the proteasome degradation
of cell cycle-related factor(s), which in turn could promote
apoptosis by a mechanism similar to that of Vpr. Such a
mechanism would be in agreement with our finding that
the TrCP-binding mutant of Vpu (Vpu2/6) did not pro-
mote apoptosis (Fig. 2 A).
To assess the impact of Vpu on cell cycle control in
HIV-infected Jurkat cells, we performed a cell cycle analy-
sis on the cultures shown in Fig. 2 A. Aliquots of cells from
each culture were removed 24 h after infection and pro-
cessed for staining with propidium iodide as described in
the Materials and Methods section. The results of this ex-
periment are shown in Fig. 2 B. Infection of cells with vi-
rus expressing Vpr and Vpu (panel b) resulted in a signifi-
cant accumulation of cells in G2. However, the absence of
Vpu (panel c) or expression of Vpu2/6 (panel d) had no sig-
nificant effect on the HIV-induced cell cycle arrest. In con-
trast, the absence of Vpr largely reversed the HIV-induced
G2 arrest irrespective of the presence or absence of Vpu
(panels e–g). Thus, Vpu has no obvious impact on cell cy-
cle control in infected Jurkat cells, suggesting that Vpu-
induced apoptosis is due to an unrelated mechanism.
Vpu Promotes Apoptosis in HIV-1-infected Primary CD4  T
Lymphocytes. We next wanted to ascertain that the apop-
totic effect of Vpu noted above was not a phenomenon re-
stricted to transformed cell lines but could be observed in
primary cell types as well. To address this issue, activated
primary CD4  T lymphocytes were infected for single-
cycle analysis with the VSV-G pseudotyped, env-defective
variants NL43-K1 (wild-type Vpu), NL43-K1/Udel (Vpu-),
or NL43-K1/U2/6 (Vpu2/6). Cells were analyzed for an-
nexin V staining as described for Fig. 2. The results from
two different donors are summarized in Table II. Consis-
tent with the results in Jurkat cells, expression of wild-type
Vpu resulted in significantly increased annexin V staining
when compared with cultures infected with the Vpu-defec-
tive variant or with a variant expressing Vpu2/6. Infection
of cells was comparable based on intracellular p24 staining
(data not shown).
Expression of CD4U but not CD4U2/6 Causes Spontaneous
Apoptosis in HeLa Cells. The experiments presented in
the previous sections demonstrate that Vpu significantly
contributes to the induction of apoptosis in HIV-1–
infected T cells independent of Vpr. However, it is never-
theless possible that Vpu alone is insufficient for induction
of apoptosis and requires other viral protein(s). We have
previously reported on the inducible expression of CD4-
Vpu or CD4-Vpu2/6 chimeras using a tetracycline/Dox-
inducible vector system in stable HeLa cell lines (16). The
CD4U and CD4U2/6 chimeric molecules were found to
have biological activities indistinguishable to those of wild-
type Vpu and Vpu2/6 (16, 27, 28). To assess the effect of
Vpu on apoptosis in the absence of other HIV-1–specific
proteins, we made use of these inducible cell lines. In a first
set of experiments we compared the induction of apoptosis
over time in the CD4U and CD4U2/6 lines after removal
of Dox. Cells were analyzed at various times after induc-
tion by annexin V staining (Fig. 3). The results of this ex-
periment demonstrate that induction of CD4U but not
CD4U2/6 caused a dramatic increase in the number of an-
nexin V-positive cells. Therefore, Vpu alone is sufficient
for the induction of apoptosis. Furthermore, the fact that
induction of CD4U2/6 did not increase the number of ap-
optotic cells with time indicates that the observed effect of
CD4U is specific and not the result of a nonspecific toxic-
ity caused by the overexpression of a heterologous protein
in these cells.
Table I. Effect of Vpu and Vpr on Induction of Apoptosis in
HIV-1–infected Jurkat Cells
HIV-1 phenotype % annexin V  cells
Clones vpr vpu env Day 1 Day 2
Mock 1.9 1.9
NL43-K1     4.4 72.4
NL43-K1/Udel     3.0 39.4
NL43-K1/U2/6   ma   4.1 44.9
NL43-EcK1 mb    2.3 41.4
NL43-Eck1/Udel mb    2.1 15.0
NL43-Eck1/U2/6 mb ma   2.3 20.2
aVpu2/6.
bvpr-defective mutant.
Table II. Effect of Vpu on Induction of Apoptosis in
HIV-1–infected Primary CD4  T Lymphocytes
% annexin V  cells
Clones Day 1 Day 2 Day 3
Exp. 1
mock 5.9 3.4
NL43-K1 8.4 30.1 (100)
NL43-K1/Udel 6.2 21.7 (69)
NL43-K1/U2/6 5.8 23.9 (77)
Exp. 2
mock 6.6 5.9 6.3
NL43-K1 7.1 12.8 28.9 (100)
NL43-K1/Udel 6.7 10.6 17.2 (48)
NL43-K1/U2/6 6.9 11.2 18.4 (54)
The numbers in parenthesis indicate the relative percentages of annexin
V-positive cells.1304 Vpu Induces Apoptosis in Infected Cells
TNF-  Treatment Amplifies the Effect of Vpu on Apop-
tosis. We have recently shown that Vpu can inhibit cellular
NF- B activity by blocking the TrCP-dependent degrada-
tion of its inhibitor I B (16). Therefore, we examined
whether the induction of apoptosis in CD4U-expressing
cells could be due to the inhibition of NF- B activity,
which controls the expression of antiapoptotic genes (1).
We made use of our inducible cell lines to assess the impact
of TNF-  treatment on apoptosis either in uninduced cells
or after induction of CD4U. It is well documented that
TNF-  can stimulate the activation of both NF- B and
caspase cascades, even though TNF-  stimulation alone
does not cause apoptosis in most cells (17). The resistance
to TNF-  requires the activation of NF- B (29–31),
which in turn induces the expression of various antiapop-
totic factors such as TRAF1, TRAF2, cellular inhibitor of
apoptosis (c-IAP)1, c-IAP2, Mcl-1, IEX-1L, Bcl-xL, and
A1/Bfl-1, all of which are able to inhibit activation of
caspases at various steps in the caspase pathway (32–37).
HeLa-CD4U and as a control HeLa-CD4U2/6 cells were
grown in the presence or absence of Dox for 24 h to in-
hibit or to induce Vpu expression, respectively. Cells were
then treated with or without TNF-  for 16 h in the pres-
ence or absence of Dox. Induction of CD4U or CD4U2/6
was confirmed by immunoblotting using a Vpu-specific
antibody (Fig. 4 A, top). The same blot was subsequently
reblotted with an antibody to  -tubulin as a loading con-
trol (Fig. 4 A, bottom). The expression levels of CD4U
and CD4U2/6 were comparable and were not affected by
treatment of the cells with TNF- . Induction of apoptosis
was measured either by annexin V staining (Fig. 4 B),
TUNEL assay (Fig. 4 C) or confocal microscopic analysis
of nuclear staining with PI (Fig. 4 D). Expression of CD4U
(white bars in Fig. 4 B and C) but not CD4U2/6 (black bars
in Fig. 4 B and C) in the absence of TNF-  led to a small
Figure 3. Expression of CD4U but not CD4U2/6 causes spontaneous
apoptosis in HeLa cells. Inducible HeLa-CD4U and CD4U2/6 cell lines
were cultured after the removal of Dox for the times indicated. The cells
were then evaluated for induction of apoptosis by staining with PE-con-
jugated annexin V, followed by flow cytometry. Error bars reflect SDs
from three independent experiments.
Figure 4. TNF-  treatment amplifies CD4U-induced apoptosis.
CD4U and CD4U2/6 cell lines were cultured in complete DMEM me-
dium in the presence or absence of Dox for 24 h TNF-  (20 ng/ml) was
then added to the samples as indicated and cultures were incubated for an
additional 16 h before analysis. (A) The expression of CD4U and
CD4U2/6 (top) and  -tubulin (bottom) was determined by immunoblot analysis using a rabbit anti-Vpu polyclonal antibody (U2–3) and a mouse anti–
 -tubulin mAb, respectively. (B and C) The cells were evaluated for induction of apoptosis by annexin V assay (B) or TUNEL assay (C), followed by
flow cytometry. (D) Cultures were examined for apoptosis-related morphological changes of the nuclei by staining with PI, followed by confocal mi-
croscopic analysis. Panel a: Dox /TNF-  ; panel b: Dox /TNF-  ; panels c and d: Dox /TNF-   by low and high power magnification, respec-
tively. Arrowheads mark cells containing pyknotic apoptotic bodies.1305 Akari et al.
but detectable increase in the number of apoptotic cells no-
ticeable in all three assay systems (compare TNF-   and
Dox /  in Fig. 4 B and C, also compare Fig. 4 D panels a
and b). However, the effect of CD4U on apoptosis was sig-
nificantly more pronounced in cultures treated with
TNF-  where 12–15% of the cells were found to be apop-
totic (TNF-   and Dox /  in Fig. 4 B and C, and Fig. 4
D panels c and d). PI staining revealed pyknotic nuclear ap-
optotic bodies, which are typical morphological character-
istics of apoptosis, in Dox-depleted CD4U cell lines (indi-
cated by arrowheads in Fig. 4 D) but not in CD4U2/6 cells
(data not shown). These results suggest that TNF-  pro-
motes CD4U-induced apoptosis in HeLa cells. The fact
that TNF-  alone, i.e., in the absence of CD4U expres-
sion, did not cause apoptosis under these experimental con-
ditions suggests that TNF- –mediated induction of apop-
tosis is facilitated by the Vpu-dependent suppression of
NF- B–dependent expression of antiapoptotic genes.
Vpu-induced Apoptosis Involves Activation of the Caspase
Pathway. In view of our observation that Vpu has the
ability to suppress spontaneous and TNF- -induced NF-
 B activation (16), it seems likely that Vpu-induced apop-
tosis is the result of an indirect activation of the caspase
pathways by downmodulating the expression levels of anti-
apoptotic factor(s). To address this issue, we initially tested
whether Vpu-induced apoptosis is dependent on the cas-
pase pathway. For that purpose, we determined the effect
of a broad-range inhibitor of caspases, Z-VAD-fmk, on
CD4U-induced and TNF- –enhanced apoptosis. HeLa-
CD4U cells were cultured in the absence of Dox for 24 h
and then treated for 16 h with TNF-  (10 ng/ml) either in
the presence or absence of Z-VAD-fmk as indicated in Fig.
5. Cells were then reacted with PE-conjugated annexin V
and analyzed by flow cytometry (Fig. 5 A). The results of
this experiment show that treatment of cells with the cas-
pase inhibitor reduced the level of annexin V-positive cells
to background levels despite the presence of CD4U and
TNF- . Of note, treatment with Z-VAD-fmk did not af-
fect the level of CD4U expression by Dox deprivation
(data not shown).
Caspase-3 is a critical downstream protease in the cas-
pase cascade, which is involved in the killing of cells in
response to a number of apoptotic stimuli including
TNF-  ligation with the TNF-receptor (38, 39). We
evaluated the levels of the active form of caspase-3 in un-
induced or induced HeLa-CD4U cells either in the pres-
ence or absence of TNF-  and/or Z-VAD-fmk as indi-
cated in Fig. 5. Caspase-3 activity was determined by
direct staining of cells with an FITC-conjugated rabbit
antiactive caspase-3 polyclonal antibody followed by
FACS® analysis (Fig. 5 B). The results of this experiment
show that the percentage of cells expressing the active
form of caspase-3 was proportional to the percentage of
annexin V-positive cells. Moreover, Z-VAD-fmk treat-
ment, which reduced the proportion of annexin V-posi-
tive cells to background levels (Fig. 5 A), simultaneously
reduced the fraction of active caspase-3-positive cells to
background levels (Fig. 5 B). These results indicate that
Vpu-induced apoptosis and its enhancement by TNF- 
are dependent on the activation of the caspase pathway,
which eventually leads to the activation of the down-
stream effector caspase-3.
Figure 5. Vpu-induced apoptosis involves activation of
the caspase pathway. CD4U and CD4U2/6 cell lines were
cultured in complete DMEM medium in the presence or ab-
sence of Dox for 24 h. TNF-  (20 ng/ml) and z-VAD-fmk
(50  M) were then added where indicated and the cultures
were incubated for an additional 16 h before analysis. (A)
Cultures were evaluated for induction of apoptosis by an-
nexin V staining. Error bars reflect SDs from three inde-
pendent experiments. (B) The same cultures were analyzed
by flow cytometry for the expression of the active form of
caspase-3 using a FITC-conjugated rabbit antiactive
caspase-3 polyclonal antibody. The numbers indicate per-
centages of FITC-positive cells.1306 Vpu Induces Apoptosis in Infected Cells
Vpu Inhibits the NF- B–dependent Expression of the Antiap-
optotic Factors Bcl-xL, A1/Bfl-1, and TRAF1. One of the
mechanisms leading to apoptosis is mitochondrial dysfunc-
tion, which leads to the release of cytochrome c into the
cytoplasm. This is followed by activation of caspase-9
through the formation of a ternary complex with Apaf-1
and procaspase-9, and results in the activation of caspase-3
(40). Members of the Bcl-2 family, which includes Bcl-xL
and A1/Bfl-1, can inhibit this process by blocking the re-
lease of cytochrome c from mitochondria (34, 41).
There is a possibility that the expression levels of Bcl-xL
and A1/Bfl-1, which are transcriptionally regulated by NF-
 B, might be reduced in Vpu-expressing cells due to its in-
hibitory effect on NF- B activity (16). To examine this
possibility, we determined the levels of Bcl-xL and A1/Bfl-1
expression in the CD4U-HeLa cells by immunoblot
analyses (Fig. 6 A). In uninduced CD4U cells (Fig. 6 A,
lanes 3 and 4), both Bcl-xL and A1/Bfl-1 were expressed at
considerable levels, reflecting the relatively high basal level
of NF- B activity in HeLa cells, and stimulation with
TNF-  did not significantly augment their expression lev-
els. After induction of CD4U expression, however, the
steady-state levels of both factors were reduced to  60% of
their levels in uninduced cultures (Fig. 6 A, lane 1 versus
lane 3). Moreover, TNF-  treatment of the CD4U-
induced cells further reduced the levels of Bcl-xL and A1/
Bfl-1 to  20% of those in TNF- –treated uninduced cells
(Fig. 6 A, lane 2 versus lane 4). These results are significant
considering that  10% of the cells shown in lane 1 and
 20% of the cells shown in lane 2 were annexin V-positive
at the time of the analysis (data not shown). Thus, Vpu in-
deed downregulated the steady-state levels of Bcl-xL and
A1/Bfl-1. The further reduction of Bcl-xL and A1/Bfl-1
levels after TNF-  treatment is presumably a consequence
of the concomitant activation of caspase-3 by TNF- ,
which is known to proteolytically cleave Bcl-xL (42, 43).
It has been shown that TRAF1 is a component of the
TNFR complex (44) and recruits the c-IAPs to the com-
plex. Recruitment of c-IAPs is required to inhibit activa-
tion of caspase-8 and thus to prevent the initiation of the
caspase pathway (33, 45). Like Bcl-xL and A1/Bfl-1, ex-
pression of TRAF1 is regulated by NF- B. In contrast, the
steady-state levels of TRAF1 in unstimulated HeLa cells
are low (Fig. 6 B, lane 3) but are efficiently induced after
TNF-  stimulation (Fig. 6 B, lane 4). As for Bcl-xL and
A1/Bfl-1, Vpu expression significantly inhibited the TNF-
mediated induction of TRAF1 (Fig. 6 B, lane 2). To assess
the physiological relevance of this phenomenon, we ana-
lyzed the effect of Vpu on the activation of caspase-8,
which is regulated by TRAF1 (33). As seen in Fig. 6 B,
TNF-  stimulation alone was not sufficient to induce
caspase-8 activation (Fig. 6 B, lane 4). Similarly, Vpu ex-
pression alone was insufficient to activate caspase-8 (Fig. 6
B, lane 1). However, TNF-  treatment of cells expressing
Vpu (Fig. 6 B, lane 2) resulted in the activation of cas-
pase-8. These results confirm that the reduced expression
of TRAF1 in Vpu-expressing cells can disturb the equilib-
rium between pro and antiapoptotic regulators and pro-
mote proapoptotic signaling in response to cytokine stimu-
lation. The fact that Vpu expression alone did not induce
caspase-8 activation further highlights the significance of
the reduced expression of Bcl-xL and A1/Bfl-1 for the ap-
optogenic properties of Vpu.
To validate the results from our inducible CD4U cell
lines we examined the effect of Vpu on the expression of
antiapoptotic factors such as Bcl-xL, A1/Bfl-1, and TRAF1
in HIV-infected T cells. For that purpose, Jurkat cells were
single-cycle infected with VSV-G pseudotyped NL43-K1,
NL43-K1/Udel, or NL43-K1/U2/6 as described for Table
Figure 6. Vpu affects the expression of antiapoptotic factors and induces
caspase-8 activation. (A and B) HeLa-CD4U cells were cultured in com-
plete DMEM medium in the presence or absence of Dox for 24 h. TNF- 
(20 ng/ml) was then added to the cultures as indicated and incubation was
continued for an additional 16 h. Cell lysates were analyzed by immuno-
blotting for the expression of Bcl-xL and A1/Bfl-1 (A) as well as TRAF1
and the active form of caspase-8 (B). Lysates were normalized for tubulin
using an  -tubulin antibody. (C) Jurkat cells were single-cycle infected
with VSV-G-pseudotyped NL43-K1, NL43-K1/Udel, or NL43-K1/U2/6.
Cell lysates were analyzed 40 h after infection by immunoblotting to detect
expression of Bcl-xL, A1/Bfl-1, TRAF1, p24 CA, Vpu, or  -tubulin.1307 Akari et al.
II. 40 h after infection, cells were analyzed by immuno-
blotting with antibodies to Bcl-xL, A1/Bfl-1, or TRAF1 as
described for Fig. 6 A and B. To control for comparable
infection efficiency and the expression levels of wild-type
Vpu and Vpu2/6, blots were stained with antibodies to p24
CA and Vpu, respectively. As a loading control, blots were
reacted with an antibody to  -tubulin. Consistent with the
results from HeLa CD4U cells (Fig. 6 A and B), the steady-
state levels of the antiapoptotic proteins were reduced in
cultures expressing wild-type Vpu (lanes 2) when com-
pared with mock-infected cultures (lanes 1) or cultures in-
fected with a Vpu-defective variant (lanes 3) or a variant
expressing Vpu2/6 (lanes 4). Taken together, these results
demonstrate that Vpu suppresses the expression of NF- B–
dependent antiapoptotic genes.
Discussion
One of the hallmarks of HIV infection is the gradual
elimination of the host’s CD4  T cells due to apoptosis.
However, the mechanisms of HIV-induced apoptosis are
complex and still controversial (1, 46). Several HIV-1 pro-
teins have been attributed with apoptogenic properties, in-
cluding Vpr (2, 3), Env, and Tat (1). More recently, Vpu
was reported to increase the sensitivity of HIV-infected cells
to Fas killing (47). However, the underlying mechanism re-
mained unclear. In this study, we investigated in detail the
apoptogenic properties of Vpu and we performed an in-
depth analysis of the molecular mechanism. Our data sug-
gest that Vpu, aside from Vpr, is one of the main inducers of
apoptosis in HIV-infected cells and functions by inhibiting
the NF- B–dependent expression of antiapoptotic genes.
Both Vpr- and Vpu-induced apoptosis involve the acti-
vation of the caspase pathway (references 48 and 49, and
this study). Although the precise mechanism for Vpr-
induced apoptosis is still unclear, recent observations sug-
gest that it might be caused by a Vpr-induced permeabili-
zation of mitochondrial membranes resulting in the release
of apoptogenic proteins such as cytochrome c or apoptosis
inducing factor and the subsequent activation of caspase
(50). While it was suggested that Vpu itself might have
poreforming properties (51, 52) making a mechanism for
induction of apoptosis similar to that of Vpr conceivable,
our data suggest that Vpu instead functions by inhibiting
the NF- B–dependent expression of antiapoptotic genes.
This is supported by the observation that mutation of the
TrCP-binding motif (Ser52, 56Asn), which in fact stabilized
the pore-forming property of Vpu (52), abolished its apop-
togenic potential (Table I). Based on the available experi-
mental evidence, we therefore propose the following
model for Vpu-induced apoptosis (Fig. 7): in unstimulated
cells, NF- B resides in the cytoplasm in an inactive com-
plex with its inhibitor I B (15). Upon stimulation of cells
by cytokines such as TNF-  (Fig. 7 no. 1), I B is rapidly
phosphorylated by an I B-specific kinase (Fig. 7 no. 2),
which results in the rapid degradation of I B via a TrCP-
dependent pathway (Fig. 7 no. 3). Infection of cells by
HIV-1 results in the gradual intracellular accumulation of
Figure 7. Model for Vpu-induced apoptosis through activation of the caspase pathway. Details of the model are explained in the Discussion. Broken
arrows symbolize inhibitory effects. Steps inhibited by Vpu are marked in red.1308 Vpu Induces Apoptosis in Infected Cells
Vpu. Because of its constitutively active TrCP-binding
motif and the fact that it is not sensitive to TrCP-mediated
proteolysis, Vpu functions as a competitive inhibitor of
TrCP. This results in the gradual accumulation of I B and
the progressive impairment of the cell’s ability to activate
NF- B (Fig. 7 no. 4). The inhibition of NF- B blocks the
synthesis of antiapoptotic proteins such as the Bcl-2 family
proteins (e.g., Bcl-xL and A1/Bfl-1) or TNFR complex
proteins (e.g., TRAF1; Fig. 7 no. 5). TRAF1 is induced by
TNF-  treatment and normally inhibits activation of cas-
pase-8 (Fig. 7 no. 6). In Vpu-expressing cells, the levels of
TRAF1, in response to TNF stimulation, are reduced and
no longer sufficient to inhibit the cytokine-induced activa-
tion of caspase-8 (Fig. 7 no. 6). Activated caspase-8 in turn
induces the release of cytochrome c from the mitochondria
(Fig. 7 no. 7). Release of cytochrome c is normally inhib-
ited by the Bcl-2 family of proteins. However, in Vpu-
expressing cells the levels of Bcl-2 proteins are limiting and
no longer sufficient to block cytochrome c release (Fig. 7
no. 8). After its release from the mitochondria, cytochrome
c forms ternary complexes with Apaf-1 and caspase-9 (Fig.
7 no. 9), resulting in the activation of caspase-3 (Fig. 7 no.
10). Active caspase-3 finally triggers a reaction that results
in the cleavage of a number of target proteins including
Bcl-2 family proteins (Fig. 7 no. 11) and leads to cell death
(Fig. 7 no. 12).
While our data clearly demonstrate the ability of Vpu to
induce apoptosis in HIV-infected cells, its role in promot-
ing apoptosis of uninfected bystander cells, which has been
observed for CD4  as well as CD8  cells (53, 54), remains
to be addressed. The latter phenomenon is presumably a
consequence of a continuous immune activation and could
be due to exposure of these cells to secreted HIV proteins
or to the disturbance of cytokine regulatory networks (55–
57). Most cytokines important for cellular and humoral im-
mune response, including IL-2, IL-4, IL-10, IL-12, as well
as TNF-  are transcriptionally regulated by NF- B (18,
58) and it is therefore possible that Vpu expression during
the course of HIV infection could affect their expression.
Thus, even though Vpu is not a secretory protein and is
unlikely to directly promote apoptosis of bystander cells, its
expression in HIV-infected cells could nevertheless indi-
rectly affect uninfected bystander cells through its possible
effect on cytokine production. While it is tempting to
speculate on a possible role of Vpu in restricting the cellular
immune response to HIV infection through its ability to
inhibit NF- B–dependent gene expression, regulation of
cytokine production in vivo is complex and influenced by
a multitude of factors, which will make it difficult to assess
the contribution of individual viral factors such as Vpu in
vivo. Nevertheless, the noted reversion of a Vpu mutant in
a monkey model and its correlation with disease progres-
sion (59) attests to the importance of Vpu for virus replica-
tion in vivo.
Chemokines are another family of cellular proteins that
is regulated by NF- B and whose expression could thus be
affected by Vpu. These include: regulated on activation,
normal T cell expressed and secreted (RANTES), macro-
phage inflammatory protein (MIP)-1 , and MIP-1  (18),
which are secreted from CD4  as well as CD8  cells and
act through their specific surface receptor CCR5 (60). En-
dogenous expression of these chemokines was found to
suppress HIV-1 replication in vitro (61) and inhibited HIV
replication, presumably through competition for the HIV
coreceptor (62). In fact, there appears to be a correlation
between increased production of RANTES and resistance
to HIV infection (63) and, conversely, decreased produc-
tion of RANTES and MIP-1  with disease progression
(64) in vivo. Thus, suppression of chemokine production
by Vpu could provide a selective advantage to the virus and
thus have a severe impact on disease progression.
HIV-2 infection is generally associated with a reduced
rate of disease development as compared with HIV-1 (65)
and is characterized by an extended asymptomatic phase.
Interestingly, lymphocytes from HIV-2–infected patients
were found to be less susceptible to apoptosis than those
derived from HIV-1–infected cells during the asymptom-
atic phase (66, 67). Therefore, it is tempting to speculate
that the apoptogenic property of Vpu, for which there is
no functional complement in HIV-2, contributes to the in-
creased pathogenicity of HIV-1. In fact, there is some evi-
dence from the macaque monkey model supporting the
importance of vpu in vivo. For example, when monkeys
were infected with a vpu-defective chimeric SHIV variant
carrying an ATG to ACG mutation in the vpu initiation
codon, the vpu gene was found to revert back to a func-
tional open reading frame during the course of infection
(59), demonstrating the in vivo selective pressure for main-
taining a functional vpu gene. In addition, reversion of the
vpu open reading frame was correlated with disease pro-
gression in infected animals (59) and expression of Vpu was
associated with increased viremia (68), demonstrating the
importance of Vpu for viral replication and/or persistence
in vivo and suggesting a role for Vpu in viral pathogenesis.
Despite the fact that HIV-1 encodes at least four proteins
that promote apoptosis, it is difficult to envision a scenario
in which the induction of apoptosis per se could provide a
selective advantage for HIV-1. It appears that, in this re-
spect, other primate lentiviruses have much better adapted
to their hosts. In particular, simian IVs, which are endemic
in their natural hosts, do not generally induce disease (69).
It seems therefore more plausible that the apoptogenic
properties of HIV-1 proteins are unfortunate side effects of
other important functions of these viral proteins. In the
case of Vpu, it could be argued that its ability to induce
rapid degradation of CD4 provides a selective advantage to
HIV-1 by preventing the intracellular retention of Env in
CD4/Env complexes (25). Such complexes can form be-
tween de novo synthesized Env and CD4 proteins in the
endoplasmic reticulum (70–72). They are highly stable and
unable to traffic to the cell surface (70–72). The benefits of
Vpu-mediated degradation of CD4 for HIV-1 are therefore
twofold: (i) it releases Env from its intracellular trap and en-
sures its expression at the cell surface, and (ii) at the same
time, Vpu prevents surface expression of CD4, which
would interfere both with virus release (73) as well as with1309 Akari et al.
the infectivity of the particles produced (74, 75). These
functions of Vpu are particularly important for HIV-1 due
to the affinity of its Env protein to CD4, which is signifi-
cantly higher than HIV-2 Env (76, 77). The evolution of
Vpu thus provides an intriguing example of how viruses re-
direct existing cellular mechanisms to their own advantage
even if it is at the expense of their host.
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